The Working Group Webinars and Community Forums provide a virtual space for the PHUSE Project Leads and Community to highlight and share industry topics of interest relating to their Working Groups. These webinars are free and take place virtually. Details of upcoming webinars are listed below and will be shared via our social media channels. For any inquiries, please contact workinggroups@phuse.global. To access past webinars, please visit the PHUSE archive. |
|---|
Date | Working Group/Project | Title | Speakers | Recordings | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
21 November 18 January | Emerging Trends & Technologies | Lan Mu, University of Georgia, Jielu Zhang, University of Georgia, Marsha Samson, FDA and Jian Dai, Roche | |||||||||||||||||||
20 November | Recommendations for Adverse Event Collection and Treatment Emergent Definition | Bill Palo, AbbVie and Aimee Basile, Otsuka | 24 October | RWD Sources – How the Genesis of Your Data Determines What Questions You Can Answer | Matthew Reynolds, Azimuth Research Group andTimothy Wolfe, Verantos|||||||||||||||||
11 October | Open Forum: Open Source Technologies in Clinical Data Analysis | Michael Rimler, PHUSE Open Source Technologies Director | Meetings are not recorded. | Anindita Saha, FDA, MiRa Jacobs, FDA and Kausar Riaz Ahmed, Pfizer | Meetings are not recorded. | ||||||||||||||||
12 July | Open Forum: Regulatory Acceptance of Open-Source Submissions | Katja Glaß, Katja Glass Consulting | Meetings are not recorded. | ||||||||||||||||||
11 July | Understanding the Complete Journey of RWD, from Data Source to Final Analysis | Jean-Marc Ferran, Independent Consultant, Berber Snoeijer, Clinline and Ariel Berger, Evidera | Mike Smith, Pfizer | Meetings are not recorded. | |||||||||||||||||
17 May | Open Forum: Open Source in Pharma and Long-Term Dependability | Mike Smith, Pfizer | Meetings are not recorded. | ||||||||||||||||||
26 April | Open Source – Solutions of the People, by the People, for the People | Michael Rimler, PHUSE Open Source Technologies Director | Meetings are not recorded. | ||||||||||||||||||
18 April | Michèle Arnoe, IQVIA, Jeffrey Brown, TriNetX andBenjamin Forred, Sanford Research | Dr. Junshui Ma, Merck | 21 February | 1 February | Stuart Malcom, Veramed, Sam Hume, CDISC, Jesse Anderson, FDA, Marguerite Kolb, Johnson & Johnson and Nicole Thorne, BMS | 18 January | RWD Quality Challenges – Different Perspectives Dr Cheryl Grandinetti, FDA andKris Wenzel, MMSInnovation | Parag Shiralkar, Sumptuous Data Sciences & Jeff Abolafia, Pinnacle 21 | |||||||||||||
16 February | Reimagining a Safety Submission – Aggregate Safety Assessment Planning | Greg Ball, ASAPprocess, Mary Nilsson, Eli Lilly, Mac Gordon, Janssen Research & Development & Barbara Hendrickson, University of Chicago | |||||||||||||||||||
21 February | Devaki Thavarajah, Instem & Deborah Collyar, Founder and President, Patient Advocates in Research (PAIR) | ||||||||||||||||||||
27 March | Reimagining a Safety Submission – Vision of Interactive Safety Reviews | Greg Ball, ASAPprocess, Mary Nilsson, Eli Lilly, Wei Wang, Eli Lilly, Xiangyun Wang, Genentech, Raj Kiran, Takeda, Melvin Munsaka, Abbvie, Neetu Sangari, Pfizer, Jeremy Wildfire, Gilead, Khushboo Sharma, Accumulus & Bill Gibson, Accumulus | |||||||||||||||||||
12 April | RWD/RWE Programming & Reporting Standards: Utilising OMOP Standards | Berber Snoeijer, ClinLine, Mary Anne Rutkowski, Merck & Co, Jerry Wang, Janssen Research and Development & Mike Briganti, Janssen Research & Development | |||||||||||||||||||
6 July | Andy Richardson, Zenetar, Elizabeth Merrall, Janssen Research and Development, Jonathan Assayag, Pfizer & Mary Anne Rutkowski, Merck & Co | ||||||||||||||||||||
5 October | Lauren Green, Amgen, Jeff Abolafia, Pinnacle 21, Christine Rossin & Pfizer, Sandra VanPelt Nguyen, Pfizer. |